Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke recovery: which blood pressure target works best?

NCT ID NCT06352619

Disease control Sponsor: The George Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests three different blood pressure management strategies in people who have had a stroke and received endovascular therapy (a procedure to remove a clot). The goal is to find the safest and most effective way to lower blood pressure after treatment to improve recovery. Up to 2,000 participants with high blood pressure after their procedure will be randomly assigned to conservative, moderate, or intensive blood pressure lowering. The study measures functional outcomes using the modified Rankin Scale, which assesses disability and independence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood pressure management (conservative, moderate, or intensive lowering)
What this could lead to
If successful, this trial could identify the best blood pressure target after stroke treatment, potentially improving recovery and reducing disability.
What could go wrong
This is an early-stage trial comparing strategies, not a proven treatment. Previous studies have shown conflicting results, and intensive blood pressure lowering may cause harm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years; 2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines; 3. Sustained high systolic blood pressure ≥150 mmHg (2 readings \<10 mins apart) within 3 hours after completion of EVT. Exclusion Criteria: 1.Any definite contraindications to BP lowering treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke, acute are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The George Institute for Global Health

    RECRUITING

    Sydney, New South Wales, 2000, Australia

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 1N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.